Key result
NSAIDs, colchicine, and anti-IL1 therapies effectively manage immune-driven recurrent pericarditis in children.
Why the study?
Recurrent pericarditis can cause significant morbidity in children and adolescents, but most evidence regarding diagnosis and management comes from studies in adult patients.
Provides a comprehensive overview of the diagnosis and management of recurrent pericarditis specifically tailored to pediatric patients, an area where evidence is largely extrapolated from adults.
May inform pediatric pericarditis care; leaves open need for dedicated pediatric trials given adult-extrapolated evidence.
Recurrent pericarditis (RP) is a clinical syndrome characterized by recurrent attacks of acute pericardial inflammation. Prognosis quoad vitam is good, although morbidity might be significant, especially in children and adolescents. Multiple potential etiologies result in RP, in the vast majority of cases through autoimmune or autoinflammatory mechanisms. Idiopathic RP is one of the most frequent diagnoses, that requires the exclusion of all known etiologies. Therapeutic advances in the last decade have been significant with the recognition of the effectiveness of anti IL1 therapy, but a correct diagnostic and therapeutic algorithm is of key importance. Unfortunately, most of evidence comes from studies in adult patients. Here we review the etiopathogenesis, diagnosis and management of RP in pediatric patients.
No takes yet. Share an insight, caveat, or question.
Tombetti et al. (2019) conducted a review in Recurrent Pericarditis. Recurrent pericarditis in children and adolescents is primarily driven by autoimmune or autoinflammatory mechanisms and can be effectively managed with NSAIDs, colchicine, and anti-IL1 therapies.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: